Brought to you by 
Zucara gets preclinical compounds from CDRD
17 Oct 2016
Executive Summary
The Centre for Drug Research and Development (CDRD) licensed Zucara Therapeutics Inc. access to a patented set of preclinical compounds that will define its lead drug candidate.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement